Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novartis Reveals Real-World Data for Gilenya at AAN 2017

By Ryan Bushey | April 26, 2017

Novartis unveiled new study results on Monday for its multiple sclerosis treatment Gilenya at the annual American Academy of Neurology meeting taking place in Washington D.C.

Gilenya is an oral disease modifying therapy aimed at controlling disease activity in RRMS, which is the most common form of the condition characterized by clearly defined attacks of new or increasing neurological symptoms followed by periods of partial or complete recovery.

Investigators performed a multicenter study evaluating Gilenya’s efficacy with 590 people diagnosed with relapse remitting multiple sclerosis (RRMS) for up to 16 months.

The goal of the study was to confirm the therapy’s real-world impact on four key measures of disease activity including relapses, MRI lesions, disability progression, and brain shrinkage.

READ MORE: Biogen Presents New Neurology Drug Data at AAN 2017

Results from the trial indicated more than 75 percent of patients taking Gilenya either exhibited no relapses, no new or enlarged MRI lesions, or no signs of disability progression, according to the announcement.

Furthermore, an estimated 58 percent of the patients displayed brain shrinkage levels that were broadly within the range expected for people without MS.

“These data build on the wealth of clinical and real-world evidence that show Gilenya is a highly efficacious, long-term treatment option for controlling disease activity in relapsing MS,” said Novartis’s Vas Narasimhan, the Global Head of Drug Development and Chief Medical Officer.

“Measuring brain shrinkage has historically been dependent on specialist brain scanning techniques. These ground-breaking new data showing brain shrinkage can be reliably measured by routine MRI scans have the potential to change how this key measure of disease progression is monitored, to ultimately help patients and physicians observe and manage treatment success and outcomes,” continued Narasimhan.

Gilenya gained approval in the U.S. as a first-line treatment for RRMS. The EU granted approval to the drug for adult patients with highly-active RRMS, per Novartis’s announcement.

Novartis has other assets in its multiple sclerosis portfolio including its experimental candidate labeled BAF312.

The company said on Tuesday it would accelerate its bid to win approval by submitting an application in the first half of 2018 for patients with RRMS instead of seeking regulatory approval the following year, reported Reuters.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE